im体育

服(fu)务热线

+8610-84928167

hIL-3 NPG 小鼠

1. 基本信息

品(pin)系名称(cheng)  NOD. Prkdcscid Il2rgtm1 Vst Tg(Csf1p -IL3)Vst/Vst

常用名  hIL-3 NPG /Vst; hIL-3 NPG

背景  NOD-scid/NcrCrl

毛色(se)   白色(se)


品系建立:

采(cai)用转(zhuan)基(ji)因(yin)的(de)方法,构建pCDNA3.1-Csf1p-IL3载(zai)体,将线性化Csf1p-IL3表(biao)达(da)序列注射到NPG小鼠的(de)原核中(zhong),在获得的(de)后(hou)代中(zhong)筛选到合适表(biao)达(da)量的(de)阳性小鼠。

在隔(ge)离(li)器(qi)中,按照近交的方(fang)式扩繁建立商品化(hua)的hIL-3 NPG小(xiao)鼠品系。


2. 表型

在(zai)NPG小鼠中(zhong)表达人的(de)hIL-3细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)因(yin)子。白细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)介素3刺激多能造血干细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)分(fen)化(hua)为(wei)髓(sui)(sui)系祖细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)。可以与表达人GM-CSF、M-CSF细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)因(yin)子的(de)NPG小鼠一(yi)起,在(zai)移植人CD34+造血干细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)6-8周后,于外周血、骨髓(sui)(sui)、胸腺和脾(pi)脏以及包括肺和肝在(zai)内(nei)的(de)非(fei)淋巴组(zu)织中(zhong),形成稳定广泛(fan)的(de)髓(sui)(sui)系和淋巴系细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)分(fen)化(hua)。在(zai)血液和组(zu)织中(zhong),可检测到粒细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)分(fen)化(hua)(嗜碱性粒细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)、中(zhong)性粒细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)和肥大(da)细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)),抗原呈递细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)分(fen)化(hua)(树(shu)突(tu)状细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)和巨(ju)噬细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao))和调节性T细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)群体等。表达人M-CSF、GM-CSF和人IL-3细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)因(yin)子与Hu-NPG人源化(hua)小鼠相比,人类造血干细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(hsc)的(de)整体植入水平更(geng)高,分(fen)化(hua)细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)种类更(geng)多。


3. 应用领域

-人(ren)源(yuan)化和癌症治(zhi)疗(liao)

-人体(ti)过敏反应模型,免疫、造血移植重建模型

-再生医学

-感染性(xing)疾(ji)病(bing)

-生医学(xue)


4. 参考(kao)文(wen)献

(1)Ito R, Takahashi T, Katano I, Kawai K, Kamisako T, Ogura T, Ida-Tanaka M, Suemizu H, Nunomura S, Ra C, Mori A, Aiso S, Ito M. (2013) Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice. J Immunol.191(6):2890-9.

(2)Wunderlich M; Chou FS; Link KA; Mizukawa B; Perry RL; Carroll M; Mulloy JC. 2010. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24(10):1785-8.

(3)Billerbeck E; Barry WT; Mu K; Dorner M; Rice CM; Ploss A. 2011. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2R{gamma}null humanized mice. Blood 117(11):3076-86.

(4)Coughlan AM; Harmon C; Whelan S; O'Brien EC; O'Reilly VP; Crotty P; Kelly P; Ryan M; Hickey FB; O'Farrelly C; Little MA. 2016. Myeloid Engraftment in Humanized Mice: Impact of Granulocyte-Colony Stimulating Factor Treatment and Transgenic Mouse Strain. Stem Cells Dev 25(7):530-41.